HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

Overview of attention for article published in Frontiers in Pharmacology, January 2024

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,035 followers.

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials https://t.co/quwIfOZSAR

30 Jan 2024

Reply Repost Favourite

“The adverse events of CDK4/6 inhibitors for HR+HER2- metastatic breast cancer:an umbrella review of meta-analyses of randomized controlled trials”Please ⁦@SenatorBraun⁩ help #MBC pts #PromisingPathwayAct ⁦⁦@amyklobuchar⁩ ⁦@SenSchumer⁩ https://t.co/rKwHCxq

15 Jan 2024

Reply Repost Favourite

New Research: The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials https://t.co/rreH2aiZ0Q #pharmacology

15 Jan 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.